SCHEMBL1793473

SCHEMBL1793473

O=[N+]([O-])c1nccc(Cl)c1OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
PIN1 Q13526 4/20 0.48
ATM Q13315 1/20 0.43
MGMT P16455 1/20 0.42
CYP19A1 P11511 2/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
S1PR4 O95977 1/20 0.40
CNR1 P21554 1/20 0.39
ACHE P22303 1/20 0.39
CNR2 P34972 1/20 0.39
HPD P32754 1/20 0.39
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531567 0.80 KMT2A (0.61) KMT2AMEN1NPC1RAB9APIN1
SCHEMBL16919130 0.80 KMT2A (0.48) KMT2AMEN1NPC1RAB9APIN1
SCHEMBL30648686 0.77 MGMT (0.54) KMT2AMEN1NPC1RAB9APIN1
SCHEMBL1843397 0.77 MGMT (0.54) KMT2AMEN1NPC1RAB9APIN1
SCHEMBL17597879 0.77 POLB (0.45) KMT2AMEN1NPC1RAB9APIN1
SCHEMBL4928212 0.77 MAPT (0.55) KMT2AMEN1NPC1RAB9APIN1
SCHEMBL10264796 0.75 S1PR4 (0.42) KMT2AMEN1NPC1RAB9AS1PR4
SCHEMBL13610890 0.75 KMT2A (0.47) KMT2AMEN1NPC1RAB9AATM
SCHEMBL4619784 0.75 KMT2A (0.84) KMT2AMEN1NPC1RAB9AATM
SCHEMBL2814768 0.75 MAPT (0.50) KMT2AMEN1PIN1CYP19A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383816-B2 Aryl-quinolyl compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-02-26 US disclosed
EP-2013207-B1 IMIDAZO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS CANCER REC TECH LTD (GB) 2012-04-25 EP disclosed
US-7951819-B2 Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-05-31 US disclosed
US-7951819-B2 Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-05-31 US disclosed
US-20090325945-A1 IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2009-12-31 US disclosed
US-20090325945-A1 IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2009-12-31 US disclosed
US-7625922-B2 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-01 US disclosed
CN-101479264-A Imidazo [4,5-B] pyridin-2-one and oxazolido [4,5-B] pyridin-2-one compounds and analogues thereof as compounds therapeutic for cancer CANCER REC TECH LTD (GB) 2009-07-08 CN disclosed
EP-2013207-A1 IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS Cancer Research Technology Limited (GB) 2009-01-14 EP disclosed
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-13 US disclosed
WO-2007125330-A1 IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325945-A1 IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS NR2E1, NR0B1, NR2E3 KMT2A 1831/4885MEN1 1074/4885NPC1 2319/4885
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds NR2E1, NR0B1, BRAF KMT2A 2007/4885MEN1 1215/4885NPC1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.